u/Significant-Pair-275

Author argues Beam Therapeutics has exceptionally strong clinical data, with risto-cel eliminating vaso-occlusive crises in 31 patients and BEAM-302 showing ~91% protein correction, plus $1.1B cash to reach a 2026 BLA filing. Catalysts include formalizing the risto-cel BLA package in 2026, longer-term BEAM-302 follow-up, and initial BEAM-301 data. Main risk is safety, highlighted by a patient death in the BEACON trial from conditioning toxicity, and a $450M annual burn that could require dilutive financing if regulatory delays occur.

Author argues American Airlines is undervalued at ~$13.50 after weak 2025 GAAP EPS and weather disruptions, while premium, corporate, and loyalty trends remain solid with loyalty partner cash at $6.1B (+17% YoY) and capacity constraints supporting pricing. Catalysts include Q2 2026 earnings testing 7–10% revenue growth, debt reduction progress toward <$35B, and early AAdvantage/Citi deal uplift. Main risk is a massive debt load at 10.14x net debt/EBITDA, thin interest coverage of 0.95x, and vulnerability to weather events or unhedged fuel costs.

Author claims Shift4 shows a massive disconnect between price and performance: shares fell ~49% to ~$59 despite 26% volume growth, 50% EBITDA margins, and a $33B backlog. The re-rating depends on converting that backlog, maintaining high-teens organic growth, and executing the Global Blue integration, especially Asia tax-free recovery data. Main risks are high leverage at 4.7x net debt/EBITDA, integration complexity, governance noise around the CEO, and macro softening in consumer travel/dining spend.